دورية أكاديمية
أعرض في EDS

Prognostic Value of the Immunohistochemical Expression of RAD51 and BRCA2 in Gastric Adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Prognostic Value of the Immunohistochemical Expression of RAD51 and BRCA2 in Gastric Adenocarcinoma.
المؤلفون: Pádua JDB; Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Mariano CFA; Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Fabro AT; Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Tirapelli DPDC; Department of Surgery and Anatomy, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Sankarankutty AK; Department of Surgery and Anatomy, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Dos Santos JS; Department of Surgery and Anatomy, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil., Brunaldi MO; Department of Pathology and Forensic Medicine, Ribeirão Preto Medical School, Universidade de São Paulo, Ribeirão Preto, Brazil.
المصدر: The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society [J Histochem Cytochem] 2022 Mar; Vol. 70 (3), pp. 199-210. Date of Electronic Publication: 2022 Jan 03.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: SAGE Publications Country of Publication: United States NLM ID: 9815334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1551-5044 (Electronic) Linking ISSN: 00221554 NLM ISO Abbreviation: J Histochem Cytochem Subsets: MEDLINE
أسماء مطبوعة: Publication: <2011->: Thousand Oaks, CA : SAGE Publications
Original Publication: Baltimore : Williams & Wilkins Co., c1953-
مواضيع طبية MeSH: Adenocarcinoma/*diagnosis , BRCA2 Protein/*analysis , Rad51 Recombinase/*analysis , Stomach Neoplasms/*diagnosis, Adenocarcinoma/metabolism ; BRCA2 Protein/biosynthesis ; Cohort Studies ; Female ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; Prognosis ; Rad51 Recombinase/biosynthesis ; Retrospective Studies ; Stomach Neoplasms/metabolism
مستخلص: Current scientific literature lacks data on the prognostic value of the expression of RAD51 and BRCA2 in gastric adenocarcinoma. Therefore, we aimed to evaluate those and other homologous recombination-related proteins (ATM, ATR, BRCA1, CHK2, γH2AX, p53) in gastric cancer, assessing their correlation with clinical prognosis. Paraffin-embedded samples were obtained from surgical specimens collected in total or subtotal gastrectomy procedures. Between 2008 and 2017, 121 patients with advanced gastric adenocarcinoma underwent surgical resection and were included in this study. Negativity for nuclear RAD51 correlated with vascular invasion, lymph node metastasis, larger tumor size, and lower overall survival and disease-free survival in univariate analysis. However, nuclear RAD51-negative cases presented better response rates to adjuvant therapy than the positive ones. Nuclear ATR negativity correlated with larger tumor size and a higher histological grade. Positivity for ATM was associated with more prolonged disease-free survival. Positivity for nuclear BRCA2 correlated with lower overall survival and diffuse histological type, whereas its high expression was associated with vascular invasion. Nevertheless, tumors positive for nuclear BRCA2 were more frequently low grade in the intestinal histological type. Our findings indicate that RAD51 and BRCA2 are valuable immunohistochemical prognostic markers in gastric adenocarcinoma.
References: Anticancer Res. 2016 Oct;36(10):5237-5247. (PMID: 27798884)
World J Gastroenterol. 2013 Mar 28;19(12):1968-74. (PMID: 23569343)
Int J Cancer. 2017 Oct 1;141(7):1286-1294. (PMID: 28477336)
Int J Cancer. 2013 May 1;132(9):2118-26. (PMID: 23065657)
Cancer Res. 2011 Aug 15;71(16):5546-57. (PMID: 21742769)
Oncol Rep. 2008 Nov;20(5):1131-6. (PMID: 18949412)
Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1251-5. (PMID: 19545791)
Am J Cancer Res. 2020 Apr 01;10(4):1255-1270. (PMID: 32368400)
Int J Endocrinol. 2015;2015:136810. (PMID: 25861265)
Lung Cancer. 2017 Mar;105:31-38. (PMID: 28236982)
BBA Clin. 2014 Aug 14;2:10-7. (PMID: 26674120)
EMBO J. 2003 Jun 2;22(11):2860-71. (PMID: 12773400)
Mol Oncol. 2015 Mar;9(3):569-85. (PMID: 25468710)
Oncotarget. 2014 May 30;5(10):3261-72. (PMID: 24811120)
Int J Cancer. 2014 Jan 1;134(1):72-80. (PMID: 23649938)
Radiother Oncol. 2007 Sep;84(3):242-51. (PMID: 17707537)
Int J Cancer. 2000 Dec 15;88(6):907-13. (PMID: 11093813)
PLoS One. 2017 Jan 18;12(1):e0167868. (PMID: 28099437)
Am J Pathol. 2018 Feb;188(2):367-377. (PMID: 29331492)
Cell Cycle. 2010 Feb 1;9(3):472-8. (PMID: 20081365)
Int J Oncol. 2006 May;28(5):1113-9. (PMID: 16596227)
Int J Cancer. 2002 May 1;99(1):58-62. (PMID: 11948492)
Histopathology. 2009 Dec;55(6):696-704. (PMID: 20002770)
Trends Cell Biol. 2010 May;20(5):269-76. (PMID: 20299221)
Br J Cancer. 2005 Jul 11;93(1):137-43. (PMID: 15956972)
Ann Surg Oncol. 2014 Feb;21(2):597-604. (PMID: 24065387)
Cancer Res. 2004 Apr 1;64(7):2390-6. (PMID: 15059890)
Clin Cancer Res. 2010 Dec 15;16(24):6159-68. (PMID: 20802015)
Antioxid Redox Signal. 2013 Jun 20;18(18):2392-8. (PMID: 22894650)
J Biol Chem. 2000 Mar 10;275(10):7337-42. (PMID: 10702305)
Hum Mutat. 2003 Mar;21(3):258-70. (PMID: 12619111)
Breast Cancer Res Treat. 2016 Aug;159(1):41-53. (PMID: 27464795)
Pathobiology. 2014;81(1):25-35. (PMID: 23969480)
فهرسة مساهمة: Keywords: DNA repair; homologous recombination; immunohistochemistry; stomach neoplasms
المشرفين على المادة: 0 (BRCA2 Protein)
0 (BRCA2 protein, human)
EC 2.7.7.- (RAD51 protein, human)
EC 2.7.7.- (Rad51 Recombinase)
تواريخ الأحداث: Date Created: 20220103 Date Completed: 20220221 Latest Revision: 20230302
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8832630
DOI: 10.1369/00221554211065834
PMID: 34978208
قاعدة البيانات: MEDLINE
الوصف
تدمد:1551-5044
DOI:10.1369/00221554211065834